Corrigendum to ''Omega-3 fatty acids in major depressive disorder A preliminary double-blind, placebo-controlled trial'' [Eur. Neuropsychoparmacol. 13 (2003) 267-271]

By Su K.-P.   Huang S.-Y.   Chiu C.-C.   Shen W.W.  

European Neuropsychopharmacology, Vol. 14, Iss. 2, 2004-03 ,pp. : 173-173

Elsevier

Access to resources Recommend Favorite

Augmentation of Citalopram with Aspirin for Treating Major Depressive Disorder, a Double Blind Randomized Placebo Controlled Clinical Trial

By  

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 13, Iss. 2, 2014-08 ,pp. : 108-111

Bentham Science Publishers

Access to resources Recommend Favorite

Omega-3 polyunsaturated fatty acids for major depressive disorder

By Su Kuan-Pin   Wang Sheng-Min   Pae Chi-Un  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 12, 2013-12 ,pp. : 1519-1534

Informa Healthcare

Access to resources Recommend Favorite

The treatment of dysthymia with sertraline: a double-blind placebo-controlled trial in dysthymic outpatients without major depression

By Guelfi J.D.   Wiseman R.L.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 289-290

Elsevier

Access to resources Recommend Favorite

Granisetron Adjunct to Fluvoxamine for Moderate to Severe Obsessive-Compulsive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

By Askari Neda  

CNS Drugs, Vol. 26, Iss. 10, 2012-10 ,pp. : 883-892

Adis International

Access to resources Recommend Favorite